Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

Inclusion Criteria: * Patients with American Joint Committee on Cancer (AJCC) seventh edition metastatic carcinoma or sarcoma involving the lungs or pleura. * Pathologic diagnosis of stage 4 cancer prior to enrollment by biopsy or on imaging with known (biopsied) primary disease * The target lesion is determined (by CT or magnetic resonance imaging \[MRI\] images) to be in a location where cryoablation is technically achievable based on the proximity of adjacent organs and structures * Maximum number of lesions per patient will be 5 total (a maximum of 3 on either the right or left side and 2 lesions on the respective contralateral side) * Of these, any lesion not treated with cryoablation will be planned to be treated with radiotherapy or radiofrequency ablation, such that all known active pulmonary disease is planned to be treated with a definitive local therapy * If treatment of both lungs is to occur by cryoablation, these treatments must be separated by at least one week * The lesion(s) treated with cryoablation may be intrapulmonary or pleural and must be =\< 3.5 cm in greatest dimension * All patients are required to have been evaluated either in consultation with a radiation oncologist or at least in a multi-disciplinary tumor conference to ensure that all local therapy options are appropriately considered for each patient * Performance Status 0-2 (Eastern Cooperative Oncology Group \[ECOG\]); Karnofsky Performance Scale \>= 60 * Life expectancy \> 3 months * Clinically suitable for cryoablation procedure as determined by the treating physician * Platelet count \> 50,000/mm\^3 within 60 days prior to study registration * International normalized ratio (INR) \< 1.5 within 60 days prior to study registration * Absolute neutrophil count (ANC) \< 1000 within 21 days prior to study registration * A signed study specific consent form is required Exclusion Criteria: * Primary lung cancer * Unable to lie flat or has respiratory distress at rest * Uncontrolled coagulopathy or bleeding disorders * Evidence of active systemic, pulmonary, or pericardial infection * Pregnant, nursing or wishes to become pregnant during the study * Debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up * Currently participating in other experimental studies that could affect the primary endpoint